Research map / Probabilistic and scientific modeling / Molecules and proteins
EvoEGF-Mol: Evolving Exponential Geodesic Flow for Structure-based Drug Design
Yaowei Jin, Junjie Wang, Cheng Cao, Penglei Wang, Duo An, Qian Shi
Read the paperCheck your idea against 137,217 papers
AI-extracted. The measured effects below were read by AI from the paper's full text (no summary yet). Numbers and claims can be wrong or missing context, so check the paper before you cite or build on it.
Measured effects reported in the paper
| What was changed | Where | Measured | Effect |
|---|---|---|---|
| use evolving endpoint instead of fixed Dirac target e-geodesic (ablation) | EvoEGF-Mol · CrossDock test (100 proteins) | PB-Valid, strain energy, Vina | Improved |
| use designed Dirichlet evolution instead of standard Dirichlet flow matching concentration (ablation) | EvoEGF-Mol · CrossDock test (100 proteins) | strain energy, PB-Valid | Improved |
| use proposed Dirichlet parameterization instead of uniform-to-one-hot schedule (ablation) | EvoEGF-Mol · CrossDock test (100 proteins) | performance | Improved |
| set smoothing coefficient lambda to 0.2 versus smaller or larger (ablation) | EvoEGF-Mol · CrossDock test (100 proteins) | geometric quality and stability | Improved |
| add explicit bond diffusion during training (ablation) | EvoEGF-Mol · CrossDock test (100 proteins) | PB-Valid, strain energy | Improved |
| reduce sampling steps from 100 to 50 (ablation) | EvoEGF-Mol · CrossDock test (100 proteins) | PB-Valid: 92.0% | No clear effect |
| use EvoEGF-Mol instead of MolCRAFT | EvoEGF-Mol · CrossDock test (100 proteins) | PB-Valid (%): 84.6 -> 93.4 | Improved |
| use EvoEGF-Mol instead of MolCRAFT | EvoEGF-Mol · MolGenBench (CrossDock proteins) | scaffold pass rate (%): 23.07 -> 31.79 | Improved |
| use EvoEGF-Mol instead of MolCRAFT | EvoEGF-Mol · CrossDock test (100 proteins) | Vina Score avg: -6.55 -> -6.14 | Hurt |
| use EvoEGF-Mol instead of DecompDiff | EvoEGF-Mol · MolGenBench (CrossDock proteins) | Hit Rate (%): 4.99 -> 3.88 | Hurt |
Earlier methods this paper compares with
Named baselines from earlier accepted papers in this paper's results tables: better than 3 of 3 on most shared results.
- MolCRAFT — MolCRAFT: Structure-Based Drug Design in Continuous Parameter Space (ICML 2024) · better on 3 of 4 shared results
- DecompDiff — DecompDiff: Diffusion Models with Decomposed Priors for Structure-Based Drug Design (ICML 2023) · better on 4 of 4 shared results
- Pocket2Mol — Pocket2Mol: Efficient Molecular Sampling Based on 3D Protein Pockets (ICML 2022) · better on 4 of 4 shared results
Matched by method name in results tables read by AI. Authors' own tables tend to favour the newer method, and a comparison can be missed when a method is renamed.
Closest papers by meaning
- Piloting Structure-Based Drug Design via Modality-Specific Optimal Schedule (ICML 2025 · similarity 0.87)
- Integrating Protein Dynamics into Structure-Based Drug Design via Full-Atom Stochastic Flows (ICLR 2025 · similarity 0.87)
- MolCRAFT: Structure-Based Drug Design in Continuous Parameter Space (ICML 2024 · similarity 0.87)
- ShEPhERD: Diffusing shape, electrostatics, and pharmacophores for bioisosteric drug design (ICLR 2025 · similarity 0.87)
- Multi-domain Distribution Learning for De Novo Drug Design (ICLR 2025 · similarity 0.86)
- Controllable 3D Molecular Generation for Structure-Based Drug Design Through Bayesian Flow Networks and Gradient Integration (NeurIPS 2025 · similarity 0.86)
Writing a paper in this area? scime draft is a free LaTeX editor with AI included, real-time co-authors and a check of your references and venue rules before you submit. It also imports OpenAI Prism projects.
